Valuation: Larimar Therapeutics, Inc.

Market Cap 434M 376M 351M 322M 605M 41.33B 615M 4.12B 1.62B 20.71B 1.63B 1.59B 68.48B P/E 2026 *
-3.11x
P/E 2027 * -3.71x
Enterprise Value 347M 300M 280M 257M 483M 32.98B 491M 3.28B 1.29B 16.53B 1.3B 1.27B 54.65B EV / Sales 2026 *
-
EV / Sales 2027 * 5.43x
Free-Float
96.73%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Larimar Therapeutics, Inc.

1 day-0.95%
1 week+8.90%
Current month+8.90%
1 month+15.24%
3 months+4.79%
6 months+23.44%
Current year+9.19%
1 week 3.74
Extreme 3.74
4.31
1 month 3.54
Extreme 3.535
4.32
Current year 2.72
Extreme 2.715
6.42
1 year 2.72
Extreme 2.715
6.42
3 years 1.61
Extreme 1.61
13.68
5 years 1.53
Extreme 1.53
15.26
10 years 1.53
Extreme 1.53
25.87
Manager TitleAgeSince
Chief Executive Officer 67 2020-04-30
Director of Finance/CFO 67 2020-05-27
Chief Tech/Sci/R&D Officer 65 2023-07-16
Director TitleAgeSince
Director/Board Member 67 2019-12-31
Chairman 61 2020-05-27
Director/Board Member 58 2020-05-27
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Buy

Director

50,000 0.0584%
2/27/26 Buy

Director

5,000 0.0058%
2/27/26 Buy

Director

100,000 0.1168%
Change 5-day change 1-year change 3-year change Capi.($)
-0.95%+8.90%+16.20%+5.32% 434M
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +3.37%+11.40%+50.22%+187.39% 26.4B
Weighted average by Cap. +4.35%+13.09%+50.63%+168.21%

Financials

2026 *2027 *
Net sales - 54.48M 47.12M 44M 40.37M 75.93M 5.18B 77.13M 516M 203M 2.6B 205M 200M 8.59B
Net income -138M -120M -112M -103M -193M -13.17B -196M -1.31B -515M -6.6B -520M -508M -21.82B -148M -128M -119M -109M -206M -14.06B -209M -1.4B -549M -7.05B -555M -543M -23.29B
Net Debt -87.7M -75.86M -70.84M -64.99M -122M -8.35B -124M -831M -326M -4.18B -329M -322M -13.83B -138M -120M -112M -103M -193M -13.18B -196M -1.31B -515M -6.61B -520M -509M -21.84B
Logo Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Employees
71
Date Price Change Volume
26-08-07 US$4.160 -0.95% 631,188
26-08-06 US$4.200 +2.44% 759,754
26-08-05 US$4.100 -0.24% 1,281,053
26-08-04 US$4.110 +3.27% 1,681,528
26-08-03 US$3.980 +4.19% 793,828
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
4.160USD
Average target price
14.30USD
Spread / Average Target
+243.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LRMR Stock